Role of postmastectomy radiotherapy: A medical oncology perspective

Fowble, 1988, Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postmastectomy radiotherapy, J Clin Oncol, 6, 1107, 10.1200/JCO.1988.6.7.1107 Cuzick, 1994, Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy, J Clin Oncol, 12, 447, 10.1200/JCO.1994.12.3.447 1995, Effects of radiotherapy and surgery of early stage breast cancer, N Engl J Med, 333, 1444, 10.1056/NEJM199511303332202 Overgaard, 1997, Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy, N Engl J Med, 337, 949, 10.1056/NEJM199710023371401 Ragaz, 1997, Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer, N Engl J Med, 337, 956, 10.1056/NEJM199710023371402 Halsted, 1984, The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889 to January, 1894, Johns Hopkins Bull, 4, 297 Fisher, 1980, Laboratory and clinical research in breast cancer—a personal adventure: The David A. Karnovsky Memorial Lecture, Cancer Res, 40, 3863 Hellman, 1994, Natural history of small breast cancers, J Clin Oncol, 12, 2229, 10.1200/JCO.1994.12.10.2229 Hellman, 1995, Oligometastases, J Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8 Price, 1986, Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements, Cancer Res, 46, 5172 Koscienly, 1984, Breast cancer: Relationship between the size of the primary tumour and the probability of metastatic dissemination, Br J Cancer, 49, 709, 10.1038/bjc.1984.112 Simpson JF, Gray R, Dressler LG, et al: Prognostic value of histologic grade and proliferative activity in axillary node positive breast cancer: Results from the Eastern Cooperative Oncology Group (ECOG) companion study, EST 4189. (submitted) Englesman, 1991, “Classical” CMF versus a 3-weekly intravenous CMF schedules in postmenopausal patients with advanced breast cancer, Eur J Cancer, 27, 966, 10.1016/0277-5379(91)90259-G Fisher, 1990, Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15, J Clin Oncol, 8, 1483, 10.1200/JCO.1990.8.9.1483 Henderson, 1998, Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not form the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC) Recht, 1996, The sequence of chemotherapy and radiation therapy after conservative surgery for breast cancer, N Engl J Med, 334, 1356, 10.1056/NEJM199605233342102 Shapiro, 1998, Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients, J Clin Oncol, 16, 3493, 10.1200/JCO.1998.16.11.3493 Recht, 1998, Postmastectomy radiotherapy: Questions for the twenty-first century, J Clin Oncol, 16, 2886, 10.1200/JCO.1998.16.8.2886 Wazer, 1997, The effects of postradiation treatment with tamoxifen on local control and cosmetic treated breast, Cancer, 80, 732, 10.1002/(SICI)1097-0142(19970815)80:4<732::AID-CNCR12>3.0.CO;2-U Fisher, 1989, A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptorpositive tumors, N Engl J Med, 320, 479, 10.1056/NEJM198902233200802 Slamon, 1987, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Press, 1997, HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative carcinomas, J Clin Oncol, 15, 2894, 10.1200/JCO.1997.15.8.2894 Cobleigh, 1998, Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer Slamon, 1998, Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpression metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial Speyer, 1988, Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer, N Engl J Med, 319, 745, 10.1056/NEJM198809223191203 Perez, 1998, Phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast cancer (MBC): A North Central Cancer Treatment Group Trial